查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085947

肝纖維化治療市場：按藥物類別、作用機制、給藥途徑和分銷管道分類的全球市場預測，2026-2032年

Liver Fibrosis Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝纖維化治療市場規模將成長至 307.1 億美元，複合年成長率為 8.68%。

主要市場統計數據
基準年 2025 171.4億美元
預計年份：2026年 185.6億美元
預測年份 2032 307.1億美元
複合年成長率 (%) 8.68%

肝纖維化的治療正從症狀治療轉向代謝功能障礙相關性脂肪性肝炎（MASH）、病毒性肝炎、酒精性肝病、膽汁淤積性疾病和自體免疫肝病的標靶治療。纖維化具有重要的臨床意義，因為進行性疤痕形成可導致肝硬化、門靜脈高壓、肝功能衰竭和肝細胞癌，因此早期診斷和治療是專科醫療保健路徑的核心。

隨著雷西甲矽油於2024年在美國獲準用於治療中重度纖維化的非肝硬化性MASH，市場格局正在重塑。這標誌著首個獲準用於治療這種棘手的代謝性肝病的藥物問世。非侵入性診斷、彈性成像、生物標記檢測以及旨在改善纖維化而不加重脂肪性肝炎的臨床試驗設計，也推動了市場成長。

肝纖維化治療前景的變革性變化

肝纖維化的治療方法正從控制末期肝硬化轉向早期發現F2-F3期纖維化患者。這種轉變得益於瞬時彈性成像、磁振造影技術、血清生物標記和風險分層工具在肝病學、內分泌學和基層醫療機構中的廣泛應用。

人工智慧對肝纖維化治療藥物的累積影響

人工智慧（AI）正日益成為肝纖維化治療藥物研發、臨床開發和患者識別的有力驅動力。 AI驅動的影像分析能夠規範組織學觀察的解讀，量化纖維化模式，並降低切片檢查評估的差異性。同時，機器學習模型可以透過整合實驗室指標、影像、基因組資訊和保險理賠數據，更早辨識高風險患者。

關於肝纖維化治療的關鍵區域見解

北美地區代謝性疾病高發生率、肝病學網路完善、先進診斷技術應用廣泛，且美國市場率先批准了MASH的治療方案，因此北美地區仍然是重要的商業和監管標竿。歐洲受益於健全的公共衛生體系、以指南為基礎的醫療保健和積極的臨床研究，但在某些國家，由於保險報銷和醫療技術評估要求的嚴格審查，患者獲得治療的機會可能會被延誤。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

在東協地區，病毒性肝炎和代謝性疾病的快速成長共同影響肝纖維化治療的需求。新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國在診斷能力和專科醫療體系的擴張速度上各有不同。海灣合作理事會（GCC）市場的特點是糖尿病和肥胖症高發生率、醫院投資力度大，以及政府主導的專科醫療現代化，這些因素共同催生了對肝纖維化診斷、肝病學服務和循證藥物治療的需求。

關於肝纖維化治療藥物商業化的關鍵國家概況

美國憑藉其便捷的專科醫療服務、MASH（主要不良心血管事件）的高發病率、先進診斷技術的廣泛主導以及已通過核准和後期臨床試驗療法快速推廣的潛力，在商業性機會方面佔據領先地位。加拿大擁有完善的保險報銷體系、強大的學術肝病中心和組織有序的專家網路。同時，隨著代謝性疾病、肥胖症和糖尿病的日益增多以及專家轉診網路的不斷發展，墨西哥和巴西代表著拉丁美洲的成長機會。

為行業領導者提供的實用建議

產業領導者應優先考慮那些對纖維化具有明確療效、具有良好的心臟代謝特徵且長期使用安全性高的療法。研發計畫應整合非侵入性生物標記、必要的組織學檢查、真實世界數據，並根據病因、纖維化分期和代謝風險進行患者分層。

調查方法

本執行摘要基於二手研究，參考了監管公告、臨床試驗註冊資訊、同行評審的肝病學文獻、公共衛生機構、產品附加檔和權威醫療指南。研究結果在治療機制、疾病病因、監管里程碑、區域醫療服務模式和市場進入因素等方面進行了交叉檢驗。

結論

已獲批准的MASH療法、更強大的診斷工具以及多元化的研發管線，已使肝纖維化治療市場發展到可以採取更切實行動的階段。其機會不再侷限於單一疾病適應症，而是涵蓋代謝性、病毒性、酒精相關性、膽汁淤積性和自體免疫肝纖維化等病因。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：肝纖維化治療市場：依藥物類別分類

  • 生物製藥
    • 單株抗體
    • 重組蛋白
  • 細胞療法
  • 基因治療
  • 小分子抑制劑
    • 天然產品
    • 合成化合物

第8章：肝纖維化治療市場：依作用機轉分類

  • ASK1抑制劑
  • 半乳糖凝集素-3抑制劑
  • PPAR促效劑
    • PDOα
    • PPAR Delta
    • PDOγ
  • TGF-BETA抑制劑

第9章：肝纖維化治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第10章：肝纖維化治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第11章：肝纖維化治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：肝纖維化治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：肝纖維化治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Akero Therapeutics, Inc.
  • Alentis Therapeutics AG
  • Alnylam Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cirius Therapeutics, Inc.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Hepion Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva Pharma
  • Ionis Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NorthSea Therapeutics BV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Pharmaxis Ltd.
  • Pliant Therapeutics, Inc.
  • Sagimet Biosciences Inc.
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
Product Code: MRR-437A5D08AE2D

The Liver Fibrosis Drugs Market is projected to grow by USD 30.71 billion at a CAGR of 8.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.14 billion
Estimated Year [2026] USD 18.56 billion
Forecast Year [2032] USD 30.71 billion
CAGR (%) 8.68%

Liver fibrosis drugs are moving from supportive disease management toward targeted intervention across metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, alcohol-associated liver disease, cholestatic disorders, and autoimmune liver diseases. Fibrosis is clinically important because progressive scarring can lead to cirrhosis, portal hypertension, liver failure, and hepatocellular carcinoma, making earlier diagnosis and treatment central to specialty care pathways.

The market is being reshaped by the 2024 U.S. approval of resmetirom for noncirrhotic MASH with moderate-to-advanced fibrosis, which created the first approved therapy for this high-burden metabolic liver disease segment. Growth is also supported by noninvasive tests, elastography, biomarker panels, and trial designs that increasingly focus on fibrosis improvement without worsening steatohepatitis.

Transformative Shifts in the Liver Fibrosis Treatment Landscape

The liver fibrosis treatment landscape is shifting from late-stage cirrhosis management to earlier identification of patients with F2-F3 fibrosis. This transition is supported by wider use of transient elastography, MRI-based techniques, serum biomarkers, and risk stratification tools in hepatology, endocrinology, and primary care.

Drug development is also diversifying beyond single-mechanism antifibrotics. Developers are advancing metabolic modulators, thyroid hormone receptor beta agonists, GLP-1-based therapies, FXR agonists, FGF analogs, PPAR agonists, anti-inflammatory agents, and combination strategies. The result is a more competitive liver fibrosis drugs market where clinical differentiation depends on histology, noninvasive endpoints, safety, cardiometabolic benefit, and payer acceptance.

Cumulative Impact of Artificial Intelligence on Liver Fibrosis Drugs

Artificial intelligence is becoming a practical enabler across liver fibrosis drug discovery, clinical development, and patient identification. AI-supported image analysis can standardize histology interpretation, quantify fibrosis patterns, and reduce variability in biopsy assessment, while machine learning models can integrate laboratory values, imaging, genomics, and claims data to identify high-risk patients earlier.

In development programs, AI can improve site selection, trial recruitment, endpoint modeling, and real-world evidence generation. Its cumulative impact is strongest where it connects fragmented clinical data with noninvasive diagnostics, helping manufacturers demonstrate disease modification, optimize adherence programs, and build evidence packages for regulators and payers.

Key Regional Insights for Liver Fibrosis Drugs

North America remains a key commercial and regulatory reference point due to high metabolic disease prevalence, established hepatology networks, advanced diagnostic adoption, and the U.S. launch environment for the first approved MASH-directed therapy. Europe benefits from strong public health systems, guideline-driven care, and active clinical research, although reimbursement scrutiny and health technology assessment requirements can slow access in several countries.

Asia-Pacific is strategically important because of large patient pools, rising obesity and diabetes rates, persistent viral hepatitis burden in several markets, and expanding clinical trial infrastructure in China, India, Japan, South Korea, and Australia. Latin America, led by Brazil and Mexico, shows rising demand as metabolic liver disease recognition increases and specialist referral pathways improve, while the Middle East faces a substantial diabetes and obesity burden that supports screening and specialty care expansion. Africa presents long-term need linked to viral hepatitis, alcohol-related liver disease, and limited access to advanced diagnostics, making affordability, diagnostic reach, and health system capacity decisive for liver fibrosis treatment adoption.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Across ASEAN, liver fibrosis drug demand is influenced by the dual burden of viral hepatitis and fast-rising metabolic disease, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expanding diagnostic and specialty care capacity at different speeds. GCC markets are shaped by high diabetes and obesity prevalence, strong hospital investment, and government-led specialty care modernization, creating demand for liver fibrosis diagnostics, hepatology services, and evidence-based pharmacologic options.

The European Union offers scale through centralized regulatory pathways, coordinated pharmacovigilance, and sophisticated health technology assessment, while BRICS countries combine large untreated populations with local manufacturing capacity, expanding clinical trial participation, and increasing public health focus on hepatitis and metabolic liver disease. G7 markets remain the benchmark for premium drug launches, evidence standards, and payer negotiation. NATO countries overlap heavily with North American and European systems, where supply security, data governance, and resilient pharmaceutical value chains are increasingly important for liver fibrosis drug access and continuity of care.

Key Country Insights for Liver Fibrosis Drug Commercialization

The United States leads in commercial opportunity because of specialty access, high MASH prevalence, broad use of advanced diagnostics, and rapid uptake potential for approved and late-stage therapies. Canada offers structured reimbursement, strong academic hepatology centers, and organized specialist networks, while Mexico and Brazil represent growing Latin American opportunities as metabolic disease, obesity, diabetes, and specialist referral networks expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to adoption, with Germany often important for early European market access and France, Italy, Spain, and the United Kingdom emphasizing cost-effectiveness, guideline alignment, and real-world outcomes. Russia remains clinically relevant due to liver disease burden, though market access is affected by geopolitical, reimbursement, and supply constraints.

China and India provide major long-term volume potential due to population scale, diabetes growth, obesity trends, and hepatitis-related fibrosis, while Japan and South Korea offer advanced diagnostics, aging populations, and strong clinical research environments. Australia remains attractive for early diagnosis programs, high-quality trial infrastructure, specialist-driven adoption, and public health attention to metabolic liver disease.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies with clear fibrosis benefit, favorable cardiometabolic profiles, and safety suitable for chronic use. Development plans should integrate noninvasive biomarkers, histology where required, real-world evidence, and patient segmentation by etiology, fibrosis stage, and metabolic risk.

Commercial teams should invest in hepatology-endocrinology referral pathways, payer evidence, diagnostic partnerships, and physician education. Organizations that combine drug efficacy with scalable patient identification, adherence support, and region-specific pricing strategies will be best positioned in the liver fibrosis drugs market.

Research Methodology

This executive summary is based on secondary research from regulatory announcements, clinical trial registries, peer-reviewed hepatology literature, public health agencies, product labels, and recognized medical guidelines. Findings were cross-checked across therapeutic mechanisms, disease etiologies, regulatory milestones, regional care patterns, and market access factors.

The methodology emphasizes verified evidence over speculative sizing. Analysis considers drug class innovation, approved therapy benchmarks, clinical endpoints, noninvasive diagnostics, patient identification barriers, reimbursement dynamics, and regional differences in liver disease burden and health system readiness.

Conclusion

The liver fibrosis drugs market has entered a more actionable phase as approved MASH therapy, stronger diagnostics, and diversified pipelines converge. The opportunity extends beyond a single disease label, spanning metabolic, viral, alcohol-related, cholestatic, and autoimmune causes of fibrosis.

Success will depend on proving durable fibrosis improvement, identifying patients before cirrhosis, and demonstrating value to payers. Industry participants that align clinical innovation with AI-enabled diagnostics, regional access strategies, and real-world evidence will shape the next decade of liver fibrosis treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Fibrosis Drugs Market, by Drug Class

  • 7.1. Biologic Therapies
    • 7.1.1. Monoclonal Antibodies
    • 7.1.2. Recombinant Proteins
  • 7.2. Cell Therapies
  • 7.3. Gene Therapies
  • 7.4. Small Molecule Inhibitors
    • 7.4.1. Natural Products
    • 7.4.2. Synthetic Compounds

8. Liver Fibrosis Drugs Market, by Mechanism Of Action

  • 8.1. ASK1 Inhibitors
  • 8.2. Galectin-3 Inhibitors
  • 8.3. PPAR Agonists
    • 8.3.1. PPAR Alpha
    • 8.3.2. PPAR Delta
    • 8.3.3. PPAR Gamma
  • 8.4. TGF Beta Blockers

9. Liver Fibrosis Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Liver Fibrosis Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain Pharmacy
    • 10.3.2. Independent Pharmacy

11. Liver Fibrosis Drugs Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Liver Fibrosis Drugs Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Liver Fibrosis Drugs Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Akero Therapeutics, Inc.
  • 15.2. Alentis Therapeutics AG
  • 15.3. Alnylam Pharmaceuticals, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Cirius Therapeutics, Inc.
  • 15.8. Eli Lilly and Company
  • 15.9. FibroGen, Inc.
  • 15.10. Galectin Therapeutics, Inc.
  • 15.11. Gilead Sciences, Inc.
  • 15.12. Hepion Pharmaceuticals, Inc.
  • 15.13. Intercept Pharmaceuticals, Inc.
  • 15.14. Inventiva Pharma
  • 15.15. Ionis Pharmaceuticals, Inc.
  • 15.16. Madrigal Pharmaceuticals, Inc.
  • 15.17. Merck & Co., Inc.
  • 15.18. NorthSea Therapeutics B.V.
  • 15.19. Novartis AG
  • 15.20. Novo Nordisk A/S
  • 15.21. Pfizer Inc.
  • 15.22. Pharmaxis Ltd.
  • 15.23. Pliant Therapeutics, Inc.
  • 15.24. Sagimet Biosciences Inc.
  • 15.25. Takeda Pharmaceutical Company Limited
  • 15.26. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NATURAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ASK1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALECTIN-3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PPAR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PPAR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PPAR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PPAR ALPHA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PPAR ALPHA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PPAR ALPHA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PPAR DELTA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PPAR DELTA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PPAR DELTA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PPAR GAMMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PPAR GAMMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PPAR GAMMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TGF BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHAIN PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHAIN PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHAIN PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 193. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, B